Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial

培美曲塞 医学 不利影响 肿瘤科 肺癌 临床研究阶段 实体瘤疗效评价标准 内科学 临床试验 进行性疾病 化疗 顺铂
作者
Chengjuan Fan,Zuke Jiang,Che‐Ming Teng,Xiaowei Song,Li Li,Weitao Shen,Qi Jiang,Dayong Huang,Y. Lv,Lianfang Du,Ge Wang,Yi Hu,Sui‐Cheung Man,Zijian Zhang,Ning Gao,Fang Wang,Tingyan Shi,Tao Xin
出处
期刊:ESMO open [Elsevier BV]
卷期号:9 (4): 102384-102384
标识
DOI:10.1016/j.esmoop.2024.102384
摘要

•IP is an effective treatment method for the EGFR-TKI-failed NSCLC-LM with a median OS of 12 months.•Previous intrathecal methotrexate/cytarabine and whole-brain radiotherapy didn't have significant difference on IP treatment.•IP is a safe treatment method for the EGFR-TKI-failed NSCLC-LM with tolerated adverse events.•IP should be recommended for patients with EGFR-TKI-failed NSCLC-LM in clinical practice. BackgroundThis study aimed to evaluate the efficacy and safety of intrathecal pemetrexed (IP) for treating patients with leptomeningeal metastases (LM) from non-small-cell lung cancer (NSCLC) who progressed from epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment in an expanded, prospective, single-arm, phase II clinical study (ChiCTR1800016615).Patients and methodsPatients with confirmed NSCLC-LM who progressed from TKI received IP (50 mg, day 1/day 5 for 1 week, then every 3 weeks for four cycles, and then once monthly) until disease progression or intolerance. Objectives were to assess overall survival (OS), response rate, and safety. Measurable lesions were assessed by investigator according to RECIST version 1.1. LM were assessed according to the Response Assessment in Neuro-Oncology (RANO) criteria.ResultsThe study included 132 patients; 68% were female and median age was 52 years (31-74 years). The median OS was 12 months (95% confidence interval 10.4-13.6 months), RANO-assessed response rate was 80.3% (106/132), and the most common adverse event was myelosuppression (n = 42; 31.8%), which reversed after symptomatic treatment. The results of subgroup analysis showed that absence of brain parenchymal metastasis, good Eastern Cooperative Oncology Group score, good response to IP treatment, negative cytology after treatment, and patients without neck/back pain/difficult defecation had longer survival. Gender, age, previous intrathecal methotrexate/cytarabine, and whole-brain radiotherapy had no significant influence on OS.ConclusionsThis study further showed that IP is an effective and safe treatment method for the EGFR-TKI-failed NSCLC-LM, and should be recommended for these patients in clinical practice and guidelines. This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed (IP) for treating patients with leptomeningeal metastases (LM) from non-small-cell lung cancer (NSCLC) who progressed from epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment in an expanded, prospective, single-arm, phase II clinical study (ChiCTR1800016615). Patients with confirmed NSCLC-LM who progressed from TKI received IP (50 mg, day 1/day 5 for 1 week, then every 3 weeks for four cycles, and then once monthly) until disease progression or intolerance. Objectives were to assess overall survival (OS), response rate, and safety. Measurable lesions were assessed by investigator according to RECIST version 1.1. LM were assessed according to the Response Assessment in Neuro-Oncology (RANO) criteria. The study included 132 patients; 68% were female and median age was 52 years (31-74 years). The median OS was 12 months (95% confidence interval 10.4-13.6 months), RANO-assessed response rate was 80.3% (106/132), and the most common adverse event was myelosuppression (n = 42; 31.8%), which reversed after symptomatic treatment. The results of subgroup analysis showed that absence of brain parenchymal metastasis, good Eastern Cooperative Oncology Group score, good response to IP treatment, negative cytology after treatment, and patients without neck/back pain/difficult defecation had longer survival. Gender, age, previous intrathecal methotrexate/cytarabine, and whole-brain radiotherapy had no significant influence on OS. This study further showed that IP is an effective and safe treatment method for the EGFR-TKI-failed NSCLC-LM, and should be recommended for these patients in clinical practice and guidelines.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
没啥鱼丸完成签到 ,获得积分10
刚刚
mnilyra发布了新的文献求助10
2秒前
2秒前
乔达摩悉达多完成签到 ,获得积分0
2秒前
3秒前
647完成签到,获得积分10
3秒前
3秒前
韵掀完成签到,获得积分10
4秒前
郑睿涛发布了新的文献求助10
4秒前
6秒前
6秒前
Homura完成签到,获得积分10
7秒前
7秒前
灵长类完成签到,获得积分10
7秒前
李爱国的应助被欣慰的文昊采纳,获得30
7秒前
8秒前
xing_xing的应助被CWJ采纳,获得20
8秒前
8秒前
郭姗姗发布了新的文献求助10
8秒前
TaoJ的应助被CWJ采纳,获得20
8秒前
是小周发布了新的文献求助10
9秒前
完美世界的应助被浮云客采纳,获得10
9秒前
把握传送时机完成签到,获得积分10
9秒前
zhao完成签到,获得积分10
10秒前
12秒前
12秒前
12秒前
核桃发布了新的文献求助50
13秒前
充电宝的应助被DFT_Gu采纳,获得10
13秒前
13秒前
马世杰发布了新的文献求助10
14秒前
14秒前
那没事了完成签到,获得积分10
14秒前
green完成签到,获得积分10
15秒前
Lucas的应助被TAT采纳,获得10
15秒前
16秒前
乐乐的应助被汤包采纳,获得10
16秒前
FashionBoy的应助被年轻雁枫采纳,获得10
16秒前
万万发布了新的文献求助10
16秒前
mabel发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611